Home » World » WAKE FOREST, North Carolina and ADELAIDE, Australia, Sept.

WAKE FOREST, North Carolina and ADELAIDE, Australia, Sept.

GNW-Adhoc: Avance Clinical GlobalReady Site Partnership Network grows rapidly to 2,000 members

04, 2024 (GLOBE NEWSWIRE) — Avance Clinical, the award-winning market-leading contract research organization for biotechnology companies, today announced that 2,000 clinical sites across North America have joined the Avance Clinical GlobalReady Site Partnership Network (partnership-network/). Yvonne Lungershausen, CEO of Avance Clinical, said these 2,000 highly qualified sites further enhance unprecedented efficiency and effectiveness for our biotech clients during their clinical development. Tina Schied, Senior Site Specialist at Avance Clinical in the U.S., said the team has individually vetted these sites for quality, therapeutic area expertise, advanced processes and compliance so our clients can be confident in the quality, rapid startup and patient access that are essential to a successful clinical program. ?Avance Clinical is highly respected by U.S.-based biotechnology companies and now accounts for more than 80% of our clients. A critical factor is that we can accelerate their clinical development in the US, Australia and Asia, from preclinical stages through to Phase III,” said Schied. “This is our GlobalReady ( leveraging our unique, streamlined, cross-regional process. With a global approach, we can ensure efficiency at every step,” she said. “Biotech companies are looking for a partner that can enable a seamless transition with high-quality data that is readily accepted by the FDA and other regulators. Our in-house global regulatory affairs team helps biotech companies confidently navigate regulatory complexities and supports our clients in submitting applications to the FDA, EMA and TGA.” “Avance Clinical is a mid-sized, agile and responsive contract research organization with a proven track record of rapidly advancing high-quality clinical programs. Our global team is focused on accelerating drug development for its biotech clients, from preclinical stages through Phase III.” Avance Clinical is also an accredited cell and gene technology contract research organization, meaning it can conduct clinical operations for preclinical and clinical trials for GMO therapies. A new analysis from market research firm Frost & Sullivan shows that one of the biggest challenges for U.S. biotech companies has been finding the right biotech-focused CRO partner. “More than 60% of U.S. biotech companies ( struggle to find the right CRO partner to accelerate their drug development programs,” said Lungershausen. (Read the report here (). The comprehensive report ( highlights the biotech industry’s increasing preference for working with right-sized CROs that can meet the fast-paced needs of the biotech industry. For more information, please click here: * Learn more about the GlobalReady model here ( * If you would like to find out more about the benefits of conducting your next study with Avance Clinical, contact us ( * Request an application to join the GlobalReady Site Partnership Network ( site-partnership-network/) About Avance Clinical Avance Clinical is the largest Australian, Asian, North American and EU contract research organization (CRO) for high-quality clinical trials with globally accepted data for international biotechnology companies in Australia, New Zealand and the USA. The company’s clients are biotechnology companies completing Phases I to III of their drug development program and requiring rapid, flexible and adaptable solution-focused clinical research services. Frost & Sullivan Awards Avance Clinical, a five-year recipient of the Frost & Sullivan Asia-Pacific CRO Market Leadership Award, has been providing contract research services in the region for more than 26 years. Preclinical to Mid-Late Stage Avance Clinical offers preclinical services ranging from preclinical to Phase III clinical services with its experienced ClinicReady team, benefiting from significant Australian Government incentive rebates of up to 43.5% and rapid regulatory ramp-up processes. With experience in over 120 indications, the CRO can deliver best-in-class results and high-quality, internationally accepted data for FDA and EMA review. Technology Avance Clinical uses cutting-edge technology and gold standard systems across all functional areas to provide its clients with the most effective processes. Medidata, Oracle, TrialHub, Certinia, Salesforce, Zelta and Medrio are just some of the technology partners. www.avancecro.com ( Â

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.